Characteristic | No. of patients (n = 183) | % |
---|---|---|
Mean age (y) | 59 | |
Sex | ||
Male | 155 | 85 |
Primary tumor site | ||
Oral cavity | 30 | 16 |
Oropharynx HPV + HPV – Unknown HPV status | 122 20 92 10 | 67 |
Hypopharynx | 25 | 14 |
Larynx | 6 | 3 |
T classificationa | ||
T1 | 8 | 4 |
T2 | 47 | 26 |
T3 | 51 | 28 |
T4 | 76 | 42 |
N classification | ||
1 | 32 | 17 |
2 | 142 | 78 |
2a | 7 | 4 |
2b | 63 | 34 |
2c | 72 | 39 |
3 | 9 | 5 |
Radiation therapy | ||
3D CRT | 84 | 46 |
IMRT | 99 | 54 |
Systemic therapy | ||
none | 35 | 19 |
cisplatin | 118 | 64 |
carboplatin/5-FU | 2 | 1 |
cetuximab | 11 | 6 |
panitumumab | 8 | 4 |
cisplatin + tirapazamine | 8 | 4 |
cisplatin + zalutumumab | 1 | 1 |